Citi notes that the FDA said in a status report filed in a Texas court that it needs more time to determine if Eli Lilly’s (LLY) tirzepatide should remain off the shortage list, and they now intend to make a determination by December 19. The firm, which views this as “moderately positive” for Hims & Hers (HIMS) and the compounders, has a Neutral rating and $24 price target on Hims shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers jumps as status report says patients unable to obtain branded GLP-1s
- Hims & Hers announces daily meal replacement bars and shakes
- TD Cowen discusses impact of FDA weight loss suit on Hims & Hers
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- Hims & Hers names Deb Autor to board, Janet Stevens as head of quality, safety